Relypsa Inc (RLYP)

32.00
NASDAQ : Health Care
Prev Close 32.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 10.26 / 34.99
Avg Volume 3.86M
Exchange NASDAQ
Shares Outstanding 44.75M
Market Cap 1.43B
EPS -4.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?

RELYPSA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Believe The Acquisition By Galenica May Be Unfair To Shareholders

RELYPSA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Believe The Acquisition By Galenica May Be Unfair To Shareholders

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Relypsa, Inc.

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Relypsa Stock Surges on $1.53 Billion Galenica Takeover Offer

Relypsa Stock Surges on $1.53 Billion Galenica Takeover Offer

Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.

Relypsa (RLYP) Stock Surging on $1.5 Billion Acquisition by Galencia

Relypsa (RLYP) Stock Surging on $1.5 Billion Acquisition by Galencia

Relypsa (RLYP) stock is up in early morning trading on Thursday after Galenica agreed to purchase the biotech for $1.53 billion.

Morning Movers: GM, JOY, RLYP, BIIB

Morning Movers: GM, JOY, RLYP, BIIB

General Motors crushed Wall Street earnings estimates before the opening bell.

Galenica to Buy Relypsa for $1.53 Billion

Galenica to Buy Relypsa for $1.53 Billion

The Swiss buyer will gain better U.S. access and drugs including Veltassa, which treats high blood potassium levels.

Market’s Overbought Condition Is Standard Fare

After a big run-up, the market behaved in typical fashion -- no damage done.

RLYP: Insiders vs. Shorts

RLYP: Insiders vs. Shorts

The most recent short interest data was recently released for the 06/30/2016 settlement date, and Relypsa, Inc is one of the most shorted stocks of the Russell 3000, based on 6.01 "days to cover" versus the median component at 4.51. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Relypsa (RLYP) Shares Cross Above 200 DMA

Relypsa (RLYP) Shares Cross Above 200 DMA

In trading on Friday, shares of Relypsa, Inc crossed above their 200 day moving average of $18.92, changing hands as high as $19.29 per share. Relypsa, Inc shares are currently trading up about 1.9% on the day.

5 Best-Positioned Biotech Stocks on Brexit Volatility

5 Best-Positioned Biotech Stocks on Brexit Volatility

Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.

5 Small-Cap Favorites Are Moving on Up

Updates on smaller housing, retail and biotech plays recently mentioned on these pages.

Ardelyx Has Big Potential

This small-cap company's shares are half where they ended 2015.

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.